AM-6545

AM-6545

Systematic (IUPAC) name
5-(4-[4-cyanobut-1-ynyl]phenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(1,1-dioxo-thiomorpholino)-1H-pyrazole-3-carboxamide
Identifiers
CAS Number	1245626-05-4 N
PubChem	CID: 46912919
ChemSpider	26333263 Y
Chemical data
Formula	C26H23Cl2N5O3S
Molecular mass	556.463 g/mol
SMILES O=S4(=O)CCN(CC4)NC(=O)c1nn(-c2ccc(Cl)cc2Cl)c(c1C)-c3ccc(C#CCCC#N)cc3
InChI InChI=1S/C26H23Cl2N5O3S/c1-18-24(26(34)31-32-13-15-37(35,36)16-14-32)30-33(23-11-10-21(27)17-22(23)28)25(18)20-8-6-19(7-9-20)5-3-2-4-12-29/h6-11,17H,2,4,13-16H2,1H3,(H,31,34) Y Key:XBHQLFVDGLPBCK-UHFFFAOYSA-N Y
NY (what is this?)

AM-6545 is a drug which acts as a peripherally selective silent antagonist for the CB₁ receptor, and was developed for the treatment of obesity. Other cannabinoid antagonists such as rimonabant have been marketed for this application, but have subsequently been withdrawn from sale because of centrally mediated side effects such as depression and nausea. Because AM-6545 does not cross the blood–brain barrier to any significant extent, it does not produce these kinds of side effects, but has still been shown to effectively reduce appetite and food consumption in animal studies.

See also

• CB-13 – a peripherally selective cannabinoid agonist
• O-2050 – a centrally active CB₁ silent antagonist
• Methylnaltrexone – a peripherally selective mu opioid receptor antagonist
• TM-38837 - another peripherally selective cannabinoid antagonist